Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
News Highlight
Company Overview
Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (AnnJi) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).
Our goals are to translate and develop unique, innovative, and highly differentiated drug therapies and to engage global collaborators and business partners in late-stage product development and commercialization.
Providing Innovative Treatments For Unmet Medical Needs
AnnJi Pharmaceutical focuses on discovering innovative small molecules and mechanism and delivering therapies to save lives and improve the quality of life around the world.
AJ201
AJ201 is a new chemical entity being developed for the treatment of spinal and bulbar muscular atrophy (SBMA)
AJ302
AJ302 is a novel selective histone deacetylase 6 inhibitor (HDAC6i) under development for the prevention and/or treatment of chemotherapy-induced peripheral neuropathy (CIPN).
AJ303
AJ303 is a novel first-in-class compound with anti-fibrotic and anti-inflammatory properties currently under development for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
